Skip to Main Content

Author Details

Elisa Pin
KTH Royal Institute of Technology
2007
48
19
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36703980Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV.Front Immunol2023
37895021Autoantibody Profiling and Anti-Kinesin Reactivity in ANCA-Associated Vasculitis.Int J Mol Sci2023
35859351Correction to: Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys.J Infect Dis2023
36982700Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis.Int J Mol Sci2023
37076360The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).Vaccine2023
36475733Exploring High-Throughput Immunoassays for Biomarker Validation in Rheumatic Diseases in the Context of the Human Proteome Project.J Proteome Res2023
36781805Array-Based Multiplex and High-Throughput Serology Assays.Methods Mol Biol2023
34564699Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.Leukemia2022
35808856B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.Eur J Neurol2022
35349756Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.Immun Inflamm Dis2022
36150168Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.Blood2022
35075450Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.Med2022
35053611Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid.Cancers (Basel)2022
35020778SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.PLoS One2022
34698500Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.Sci Transl Med2022
34459525Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.J Intern Med2022
34628049A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies.N Biotechnol2022
33978762Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys.J Infect Dis2021
33516942Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3'UTR of the MSH6 gene.Cancer Genet2021
33712077Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in blood-brain barrier disruption and outcome prediction following severe traumatic brain injury: a prospective, observational study.Crit Care2021
33843090SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden.J Intern Med2021
33664279Antibodies to SARS-CoV-2 and risk of past or future sick leave.Sci Rep2021
33580261High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers.J Infect Dis2021
33858214Immunoglobulin A Autoreactivity toward Brain Enriched and Apoptosis-Regulating Proteins in Saliva of Athletes after Acute Concussion and Subconcussive Impacts.J Neurotrauma2021
34490414Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis.iScience2021
34628858Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers.J Proteome Res2021
34391088Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.EBioMedicine2021
34295471Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.Clin Transl Immunology2021
34012450False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases.Front Immunol2021
33033249SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.Nat Commun2020
31432421Array-Based Profiling of Proteins and Autoantibody Repertoires in CSF.Methods Mol Biol2019
31772123The human secretome.Sci Signal2019
31555726Multiplexed analysis of the secretin-like GPCR-RAMP interactome.Sci Adv2019
27700103Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer.J Proteome Res2017
27825696A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.Mol Oncol2016
26558424Immunocapture strategies in translational proteomics.Expert Rev Proteomics2016
23361220MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events.Eur J Hum Genet2014
24787230Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.J Proteome Res2014
24510676Preparation and use of reverse protein microarrays.Curr Protoc Protein Sci2014
24166505HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.Oncogene2014
22865608MUTYH c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in MUTYH-Associated Polyposis.Int J Cancer2013
23527888Individualized therapy for metastatic colorectal cancer.J Intern Med2013
23266295The role of proteomics in prostate cancer research: biomarker discovery and validation.Clin Biochem2013
23108399Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability.Oncogene2013
23154546A pilot characterization of human lung NSCLC by protein pathway activation mapping.J Thorac Oncol2012
21239990Integrated analysis of unclassified variants in mismatch repair genes.Genet Med2011
19133695Somatic mosaicism in a patient with Lynch syndrome.Am J Med Genet A2009
17329446Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.Clin Vaccine Immunol2007
  • 1 - 48 of 48

Recommended Authors

Haolong Li
University of California san francisco
Career Start Year 2014
Number of shared co-authors 1
John F K Sauld
Emulate Inc.
Career Start Year 2013
Number of shared co-authors 0
Paula D??ez
Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL)
Career Start Year 2012
Number of shared co-authors 6
Javier A Alfaro
International Centre for Cancer Vaccine Science, University of Gdansk
Career Start Year 2008
Number of shared co-authors 0
Marcus Gry
AlbaNova University Center, KTH Royal Institute of Technology
Career Start Year 2008
Number of shared co-authors 9
Ioannis Prassas
Mount Sinai Hospital
Career Start Year 2007
Number of shared co-authors 0
John R Mills
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 0
Athena A Schepmoes
Pacific Northwest National Laboratory
Career Start Year 2006
Number of shared co-authors 0
Bryan Krastins
Nuclea Biotechnologies
Career Start Year 2005
Number of shared co-authors 1
Sanjeeva Srivastava
Indian Institute of Technology Bombay
Career Start Year 2004
Number of shared co-authors 5
Surendra Dasari
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 0
Kieran Wynne
University College Dublin
Career Start Year 2002
Number of shared co-authors 0
Melinda Rezeli
Clinical Protein Science & Imaging, Biomedical Centre, Lund University
Career Start Year 2002
Number of shared co-authors 4
Rosa M D??gano
Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL)
Career Start Year 2002
Number of shared co-authors 4
Kai St??hler
Universitatsklinikum
Career Start Year 2002
Number of shared co-authors 0
Victor Segura
Center for Applied Medical Research (CIMA)
Career Start Year 2000
Number of shared co-authors 4
Bernd Wollscheid
ETH Zurich
Career Start Year 1998
Number of shared co-authors 2
David A Sarracino
Harvard Partners Center For Genetics and Genomics
Career Start Year 1998
Number of shared co-authors 1
Julius O Nyalwidhe
Eastern Virginia Medical School
Career Start Year 1997
Number of shared co-authors 0
Janne Lehti??
Karolinska Institutet
Career Start Year 1997
Number of shared co-authors 13
Thomas Kislinger
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 0
Wim Van Criekinge
Ghent University
Career Start Year 1995
Number of shared co-authors 0
Yu-Ju Chen
Institute of Chemistry
Career Start Year 1992
Number of shared co-authors 4
Helena Persson
Lund University Cancer Centre
Career Start Year 1989
Number of shared co-authors 4
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 0
Joshua LaBaer
Biodesign Institute, Arizona State University
Career Start Year 1986
Number of shared co-authors 8
Gy??rgy Marko-Varga
Clinical Protein Science & Imaging, Biomedical Centre, Lund University
Career Start Year 1984
Number of shared co-authors 9
Eleftherios P Diamandis
Lunenfeld-Tanenbaum Research Institute
Career Start Year 1981
Number of shared co-authors 2
Thomas E Fehniger
Biomedical Center, Lund University
Career Start Year 1979
Number of shared co-authors 6
Samir M Hanash
University of Texas MD Anderson Cancer Center
Career Start Year 1977
Number of shared co-authors 3

Collaborators

Anna M??nberg
KTH Royal Institute of Technology
Co-authored papers 18
Sophia Hober
KTH Royal Institute of Technology
Co-authored papers 18
Peter Nilsson
Linkoping University
Co-authored papers 11
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 8
Hanna Tegel
KTH-Royal Institute of Technology
Co-authored papers 7
Mathias Uhl??n
KTH Royal Institute of Technology
Co-authored papers 6
Jochen M Schwenk
KTH Royal Institute of Technology
Co-authored papers 4
Lance A Liotta
Co-authored papers 4
Mariaelena Pierobon
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 4
Mun-Gwan Hong
KTH Royal Institute of Technology
Co-authored papers 3
Tomas Olsson
Co-authored papers 3
Fredrik Piehl
Co-authored papers 3
Kalle von Feilitzen
KTH Royal Institute of Technology
Co-authored papers 2
Fredrik Edfors
KTH Royal Institute of Technology
Co-authored papers 2
Anne-Sophie Svensson
KTH - Royal Institute of Technology
Co-authored papers 2
Manuel Fuentes
Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL)
Co-authored papers 2
Sara Kanje
KTH-Royal Institute of Technology
Co-authored papers 2
Anna Berling
KTH - Royal Institute of Technology
Co-authored papers 2
Tea Dodig-Crnkovi??
Columbia University
Co-authored papers 2
G??ran Bergstr??m
Sahlgrenska University Hospital
Co-authored papers 1
Mar??a Gonz??lez-Gonz??lez
Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL)
Co-authored papers 1
??sa Sivertsson
KTH-Royal Institute of Technology
Co-authored papers 1
Patrik K E Magnusson
Co-authored papers 1
Marica Hamsten
Karolinska Institutet
Co-authored papers 1
Siri Ekblad
KTH - Royal Institute of Technology
Co-authored papers 1
Johan Rockberg
KTH - Royal Institute of Technology
Co-authored papers 1
Anna-Luisa Volk
KTH - Royal Institute of Technology
Co-authored papers 1
Linn Fagerberg
KTH Royal Institute of Technology
Co-authored papers 1
Martin Zwahlen
KTH Royal Institute of Technology
Co-authored papers 1
Elisabet Svenungsson
Co-authored papers 1
Release 1.2